Neurodegenerative Diseases

Abnormalities in Genes Linked to IRSP in Alzheimer Disease

Abnormalities in Genes Linked to IRSP in Alzheimer Disease

Individuals with Alzheimer disease have abnormalities and reductions in gene expression in the parahippocampal gyri that map to genes associated with the insulin receptor signaling pathway.

Alzheimer Disease Biomarkers Expose Individuals to Long-Term Care Insurance Denial

Alzheimer Disease Biomarkers Expose Individuals to Long-Term Care Insurance Denial

By

Approximately 5.5 million Americans have Alzheimer disease or dementia.

Critical Illness and the Brain: Managing Risk for Cognitive Adverse Effects

Critical Illness and the Brain: Managing Risk for Cognitive Adverse Effects

By

The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.

Preeclampsia Tied to Increased Risk for Vascular Dementia

Preeclampsia Tied to Increased Risk for Vascular Dementia

Preeclampsia seems to be associated with an increased risk for dementia, especially vascular dementia, with a stronger correlation for late-onset disease.

Biomarkers of Alzheimer Disease Observed in Down Syndrome

Biomarkers of Alzheimer Disease Observed in Down Syndrome

By

Neurological and neuropsychological examinations were performed to assess intellectual disabilities, and biological assays were performed on collected CSF and plasma.

Multiple Births Associated With Greater Late-Life Risk for Alzheimer Disease

Multiple Births Associated With Greater Late-Life Risk for Alzheimer Disease

By

Grand multiparity was associated with significantly worse Mini-Mental State Examination scores compared with those with 1 to 4 completed pregnancies.

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

By

Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

By

In multivariable models, associations were observed between cardiovascular risk factors and cerebrovascular morphology, as well as white matter hyperintensity count.

Atrial Fibrillation Tied to Higher Dementia Risk in Older Adults

Atrial Fibrillation Tied to Higher Dementia Risk in Older Adults

Atrial fibrillation is associated with a faster global cognitive decline and an increased risk for dementia in older people.

PET imaging of tau may help distinguish Alzheimer Disease from other neurodegenerative disorders

In this cross-sectional study, the tau marker [18F]flortaucipir accurately distinguished Alzheimer's Disease dementia from other non-AD neurodegenerative disorders about 90% of the time.

Tau PET Is a Reliable Biomarker for Cognitive Decline in Older Adults

Tau PET Is a Reliable Biomarker for Cognitive Decline in Older Adults

By

Investigators evaluated cognition with measures reflecting executive function, episodic memory, semantic fluency, and processing speed on an annual basis.

Positive Link Between Air Pollution, Diagnosis of Dementia

Positive Link Between Air Pollution, Diagnosis of Dementia

There is a positive association between residential levels of air pollution and being diagnosed with dementia.

Age, Sex, <i>APOE</i> Genotype Identify Alzheimer's, Dementia Risk

Age, Sex, APOE Genotype Identify Alzheimer's, Dementia Risk

Age, sex and apolipoprotein E genotype can identify groups at high 10-year risk for Alzheimer disease and all dementia.

Multiple Pathways Explain Age-Linked Increase in Dementia Risk

Multiple Pathways Explain Age-Linked Increase in Dementia Risk

Multiple pathways account for the age-related increases in dementia risk.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

The burden of Alzheimer disease and related dementias is expected to increase to 3.3% in the United States by 2060.

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

By

Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.

Improved cardiovascular health associated with lower incidence of dementia in older adults

In this prospective cohort study, older patients with more optimal cardiovascular health metrics had a lower rate of developing dementia in a dose-dependent manner.

Retinal Abnormalities May Indicate Preclinical Alzheimer's

Retinal Abnormalities May Indicate Preclinical Alzheimer's

Retinal microvascular abnormalities are identified in cognitively healthy individuals who have biomarkers positive for Alzheimer disease.

Pseudobulbar Affect: Signs, Symptoms, and Treatment for Uncontrollable Laughing or Crying

Pseudobulbar Affect: Signs, Symptoms, and Treatment for Uncontrollable Laughing or Crying

By

Pseudobulbar affect is a significant national health issue in the United States, with approximately 2 million individuals affected.

Late-Life Blood Pressure Associated With Alzheimer Disease Brain Pathology

Late-Life Blood Pressure Associated With Alzheimer Disease Brain Pathology

By

Patients with a higher mean systolic blood pressure during follow-up had increased odds for brain infarcts compared with those with lower levels.

Low Fasting Insulin Associated With Long-Term Dementia Risk

Low Fasting Insulin Associated With Long-Term Dementia Risk

By

Having high insulin at baseline was associated with a greater risk for incident diabetes mellitus compared with low insulin values.

Cardiovascular Health Tied to Dementia Risk in Older Adults

Cardiovascular Health Tied to Dementia Risk in Older Adults

For older adults, increased numbers of optimal cardiovascular health metrics are associated with reduced risk of dementia.

VAT Score Improves Predictive Value of MMSE for Dementia

VAT Score Improves Predictive Value of MMSE for Dementia

Administering the Visual Association Test improves the predictive value of the Mini-Mental State Examination score for dementia.

Both Abstinence and High Alcohol Use Linked to Dementia

Both Abstinence and High Alcohol Use Linked to Dementia

Abstinence in midlife and consumption of more than 14 units of alcohol per week are associated with increased risk of dementia.

Tau Associated With Loss of Anterior Temporal White Matter Integrity

Tau Associated With Loss of Anterior Temporal White Matter Integrity

By

Tau was found to be a significant predictor of mean diffusivity in the anterior temporal white matter.

Monoclonal Antibody Granted Orphan Drug Status for Frontotemporal Dementia

Monoclonal Antibody Granted Orphan Drug Status for Frontotemporal Dementia

By

There are currently no treatments available for frontotemporal dementia.

PET Imaging Can Measure Synaptic Loss From Alzheimer's

PET Imaging Can Measure Synaptic Loss From Alzheimer's

Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

By

The findings suggest that confabulations by patients with AD are related to an impaired ability to mentally go back in time to retrieve the context in which the confabulated memories were encoded.

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

By

Lower cognitive ability total and verbal ability scores were predictive of greater risk for early-onset dementia.

Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

By

Researchers from NeuroActiva, Inc. presented results of their randomized, double-blind, placebo-controlled phase 2A clinical trial of NA-831.

Sign Up for Free e-newsletters



CME Focus